## **Amendments to the Claims:**

Listing of Claims:

1. (Currently amended) A compound of formula I:

and or pharmaceutically acceptable salts or and solvates thereof, wherein:

R<sup>10</sup> is a nitrogen protecting group and R<sup>11</sup> is either OH or O-R<sup>12</sup>, wherein R<sup>12</sup> is an oxygen protecting group, or R<sup>10</sup> and R<sup>11</sup> together form a double bond between N10 and C11; and R<sup>10</sup> and R<sup>11</sup> are selected from the same options as R<sup>10</sup> and R<sup>11</sup> respectively.

- 2. (Canceled)
- 3. (Currently amended) A compound according to claim <u>16</u> 4, wherein the compounds have the following stereochemistry at the C11 position:

when R<sup>10</sup> and R<sup>11</sup> do not form a double bond.

- 4. (Currently amended) A compound according to claim <u>16</u> 1, wherein the nitrogen protecting groups are selected from carbamate nitrogen protecting groups.
- 5. (Original) A compound according to claim 4, wherein the nitrogen protecting groups are selected from the group consisting of Alloc, Troc, Teoc, BOC, Doc, Hoc, TcBOC, Fmoc, 1-Adoc and 2-Adoc.
- 6. (Canceled)

- 7. (Previously presented) A compound according to claim 1, wherein at least 50% is in either the E-, E- or Z-, Z- forms.
- 8. (Canceled)
- 9. (Canceled)
- 10. (Previously presented) A pharmaceutical composition comprising a compound of claim 1 and pharmaceutically acceptable salts and solvates thereof, and a pharmaceutically acceptable excipient.
- 11. (Canceled)
- 12. (Canceled)
- 13. (Canceled)
- 14. (Currently amended) A method for the treatment of a gene-based disease, comprising administering to a subject suffering from a gene-based disease a therapeutically-effective amount of a compound of claim 1 or pharmaceutically acceptable salts and solvates thereof The method of claim 12, wherein the gene-based disease is infection by gram-positive bacteria.
- 15. (Previously presented) The method of claim 14, wherein the gram-positive bacteria is selected from MRSA and VRE.
- 16. (New) A compound of formula I:

or pharmaceutically acceptable salts or solvates thereof, wherein:

USSN 10/598,691 Response to Office Action mailed March 21, 2008

R<sup>10</sup> is a nitrogen protecting group and R<sup>11</sup> is either OH or O-R<sup>12</sup>, wherein R<sup>12</sup> is an oxygen protecting group;

and R<sup>10'</sup> and R<sup>11'</sup> are selected from the same options as R<sup>10</sup> and R<sup>11</sup> respectively.